

23rd October, 2026

- | | |
|---|---|
| <p>(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th floor
Plot no. C/1, G Block
Bandra Kurla Complex
Bandra (East), Mumbai - 400 051</p> <p>Scrip Symbol: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE
LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II
L-1840 Luxembourg</p> | |

Sub: USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (InvaGen) (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 19th October, 2026 to 22nd October 2026 (ET). The Inspection was a routine current Good Manufacturing Practices (cGMP) Inspection.

The inspection concluded with zero Form 483 observations.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For **Cipla Limited**

RAJENDRA
CHOPRA
Rajendra Chopra
Company Secretary

Digitally signed
by RAJENDRA
CHOPRA
Date: 2026.10.23
08:58:35 +05'30'

Prepared by: Chirag Hotchandani